Wedbush analyst Martin Fan raised the firm's price target on Vor Bio to $18 from $15 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and reiterated guidance for topline data from the Phase 3 UPSTREAM MG study in the first half of 2027. Wedbush remains interested in the potential for telitacicept to be a first-in-class BAFF/APRIL antagonist for multiple indications. Strong results from UPSTREAM MG should increase confidence in results for multiple other indications from Chinese partner RemeGen, including Sjogren's disease. However, until Vor demonstrates efficacy in a global trial, the firm remains on the fence regarding shares.
